Claritev reports Q3 EPS ($4.23) vs. ($24.25) last year

Reports Q3 revenue $245.96M vs. $230.50M last year. The Company ended Q3 with $39.2M of unrestricted cash and cash equivalents on the balance sheet. “We declared 2025 would be the Year of the Turn at Claritev (CTEV). Our Q3 results and increased full year guidance demonstrate that we have made the Turn and are now focused on the next phase of our Strategic Plan – The Way Up. We have laid the foundation for success, and continue to execute across our business, driving growth in our core solutions while delivering value across our expanded vertical and growing market segments. I am proud of how our team has embraced the clarity of our purpose to make healthcare affordable and transparent for all, and used that mission to continue building deeper relationships across the healthcare ecosystem,” said Travis Dalton, Chairman, CEO and President of Claritev.